| Name | Title | Contact Details |
|---|
Fox Med-Equip Svc is a Collinsville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Definitive Healthcare is the leading provider of data and intelligence on hospitals, physicians and other healthcare providers. Definitive Healthcare`s data provides clients with the analytics and insight needed to effectively segment and research the healthcare provider market.
Sensei is an evidenced-based company that develops technology and offers healthier living programs and services to help people find greater wellbeing. Its first retreat is located at the Sensei Lānaʻi, A Four Seasons Resort on Larry Ellison`s secluded Hawaiian island of Lānaʻi, is where people come to learn the Sensei Way philosophy in the most luxurious and inspiring settings. Each guest`s stay is highly customized to help align their actions with their intentions by offering private wellness consultations, small indoor and outdoor classes, relaxing treatments in individual spa hales, outdoor adventures and innovative dining guided by the Sensei nutritional philosophy.
Meadowmere Assisted Living is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.